Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells - PubMed
doi: 10.1371/journal.pone.0047014. Epub 2012 Oct 16.
Priyajit Chatterjee, Sushmita Bhattacharya, Durba Pal, Suman Dasgupta, Rakesh Kundu, Sandip Mukherjee, Shelley Bhattacharya, Mantu Bhuyan, Pranab R Bhattacharyya, Gakul Baishya, Nabin C Barua, Pranab K Baruah, Paruchuri G Rao, Samir Bhattacharya
Affiliations
- PMID: 23091605
- PMCID: PMC3473030
- DOI: 10.1371/journal.pone.0047014
Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells
Soma Seal et al. PLoS One. 2012.
Abstract
Non-small cell lung carcinoma (NSCLC) is a major killer in cancer related human death. Its therapeutic intervention requires superior efficient molecule(s) as it often becomes resistant to present chemotherapy options. Here we report that vapor of volatile oil compounds obtained from Litsea cubeba seeds killed human NSCLC cells, A549, through the induction of apoptosis and cell cycle arrest. Vapor generated from the combined oils (VCO) deactivated Akt, a key player in cancer cell survival and proliferation. Interestingly VCO dephosphorylated Akt at both Ser(473) and Thr(308); through the suppression of mTOR and pPDK1 respectively. As a consequence of this, diminished phosphorylation of Bad occurred along with the decreased Bcl-xL expression. This subsequently enhanced Bax levels permitting the release of mitochondrial cytochrome c into the cytosol which concomitantly activated caspase 9 and caspase 3 resulting apoptotic cell death. Impairment of Akt activation by VCO also deactivated Mdm2 that effected overexpression of p53 which in turn upregulated p21 expression. This causes enhanced p21 binding to cyclin D1 that halted G1 to S phase progression. Taken together, VCO produces two prong effects on lung cancer cells, it induces apoptosis and blocked cancer cell proliferation, both occurred due to the deactivation of Akt. In addition, it has another crucial advantage: VCO could be directly delivered to lung cancer tissue through inhalation.
Conflict of interest statement
Competing Interests: The co-author Prof. Samir Bhattacharya is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/b19ea6fbf3bf/pone.0047014.g001.gif)
(A) Cell viability of A549 lung cancer cells were measured when exposed to vapors of different dilutions (106 to 102) of crude oil for 72 h by using MTT assay and the data was expressed as % of cell survivability relative to control. (B) Chemical structures of four most available compounds (C1- Citronellal; C2- neo-isopulegol; C3- isopulegol; C4- citronellol) isolated from Litsea cubeba seed essential oil. (C) Percentage of cell death was observed when A549 cells were exposed individually with these compounds for 72 h. (D) Effect of VCO (C2∶C3∶C4 as 1∶1∶1) and C4 on cell death at 72 h was observed by MTT assay, which was visualized by microscopic images. (E) Cell survivability was measured at different time intervals (24, 48, 72 h) with VCO exposure on A549 cells. (F) Western blot of Akt phosphorylation at Thr308, Ser473 and total Akt in A549 cells treated without (Con) with C1, C2, C3, C4 and VCO for 36 hours. β-actin served as internal loading control. Values are means ± SEM of 3 individual experiments. *p<0.05, **p<0.01 versus control and #p<0.05 versus C4.
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/ff782fed379b/pone.0047014.g002.gif)
(A) Annexin-Cy3 (red) and 6-CFDA (green) double staining of apoptotic cells was examined by fluorescence microscopy where VCO treated A549 cells showed both green and red stains and control (untreated) cells stained green only. (B) Percentage of apoptotic A549 cells was measured at different time points (0 h, 12 h, 24 h, 36 h) with VCO treatments. (C) Mitochondrial membrane potential was observed in control and VCO exposed (36 h) A549 lung cancer cells by JC-1 staining assay. (D) Apoptotic DNA fragmentation was observed by VCO treated A-549 cells on 1.5% agarose gel electrophoresis. Data are presented as means ± SEM of three independent experiments. *p<0.05, **p<0.01 versus control (0 h). Bar represents 20 µm.
![Figure 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/7d2278f329d2/pone.0047014.g003.gif)
(A, B) Immunoblot analysis of Akt phosphorylation at Thr308 (A) and Ser473 (B) in A549 treated cells with VCO for the indicated time period (upper panel). Fold change represents the protein level of the VCO treated cells relative to the control cells. Bands were quantified by densitometric analysis where pAkt level was then normalized to the total Akt level (lower panel). β-actin served as loading control. (C, D) Immunoblot analysis of pPDK1 Ser 241 (C) and mTOR (D) was done at different time hour (0 h, 12 h, 24 h, 36 h) exposure of VCO to A549 cells (upper panel). Bands were quantified by densitometric analysis where pPDK1 or mTOR level was then normalized with β-actin which is represented by folds change (lower panel). Figures are representative of three independent experiments, *p<0.01, **p<0.001 versus control (0 h).
![Figure 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/38ef96b8afa3/pone.0047014.g004.gif)
(A) Immunoblot analysis was performed to evaluate the level of pBad Ser136 and Bad in A549 cells exposed with VCO for different time periods (0 h, 12 h, 24 h, 36 h). β-actin served as internal control. Bands were quantified by densitometric analysis where pBad level was compared with Bad level. (B) Protein level of Bcl-xL and Bax of these cells were also evaluated by immunoblot analysis. Densitometric analysis showed Bcl-xL was negatively correlated with Bax level when A549 cells were exposed with VCO. Values are means ± SEM of three independent experiments, *p<0.05, **p<0.01 versus control (0 h).
![Figure 5](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/e8f7116ead3e/pone.0047014.g005.gif)
(A) A549 cells were exposed with VCO for 36 h followed by staining of mitochondria with Mitotracker (red) and cytochrome c with FITC conjugated anti-cytochrome c antibody (green). (B) Immunoblot analysis was done by using anti-cleaved caspase-9 or caspase-3 antibodies in A-549 cells incubated in the presence of VCO at 0 h, 24 h, 36 h time intervals. β-actin used as internal control. (C) A549 cells were exposed with VCO for indicated time periods and on termination of exposure, cells were lysed and caspase 3 activity was measured in DTX multimode detector by using proluminescent caspase 3 as the substrate. (D) PARP cleavage was observed in VCO exposed cells by immunoblot analysis using anti-PARP antibody. β-actin used as loading control. Values are means ± SEM of three independent experiments, *p<0.01, **p<0.001 versus control (0 h). Bar represents 20 µm.
![Figure 6](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0175/3473030/394538c70ae8/pone.0047014.g006.gif)
(A) Immunoblot analysis of pMdm2 Ser166, p21 and p53 was analyzed in control or VCO exposed A549 cells at indicated time periods. β-actin used as internal loading control. (B) Immunoblot showed p21 level in p53 siRNA or Sp1 siRNA or their control siRNA transfected A549 cells exposed with or without VCO. (C) ChIP assay demonstrated VCO exposure increases binding of p53 to its response element (RE1 and RE2) on p21 promoter. (D) Cyclin D1-p21 interaction was increased with increasing the time of VCO exposure, which was shown by co-immunoprecipitation study. (E) BrdU incorporation in control and VCO treated A549 cells were examined by florescence microscopy. (F) FACS analysis showed cell cycle arrest at G1 to S phase as indicated by increased percentage of G0/G1 cells with the decrease of S and G2/M phase cells. Bar represents 20 µm.
Similar articles
-
Qu D, Ma J, Song N, Hui L, Yang L, Guo Y, Sang C. Qu D, et al. Acta Histochem. 2020 Jul;122(5):151557. doi: 10.1016/j.acthis.2020.151557. Epub 2020 Jun 6. Acta Histochem. 2020. PMID: 32622431
-
Wang D, Qu X, Zhuang X, Geng G, Hou J, Xu N, Li W, Hu T, Chen YS. Wang D, et al. Nutr Cancer. 2016 Nov-Dec;68(8):1394-1403. doi: 10.1080/01635581.2016.1224362. Epub 2016 Sep 16. Nutr Cancer. 2016. PMID: 27635476
-
Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, Afaq F. Pal HC, et al. PLoS One. 2013 Oct 4;8(10):e77270. doi: 10.1371/journal.pone.0077270. eCollection 2013. PLoS One. 2013. PMID: 24124611 Free PMC article.
-
Zhou M, Shen S, Zhao X, Gong X. Zhou M, et al. Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):263-269. doi: 10.1016/j.bbrc.2017.10.042. Epub 2017 Oct 9. Biochem Biophys Res Commun. 2017. PMID: 29024631
Cited by
-
Essential Oils: Chemistry and Pharmacological Activities.
de Sousa DP, Damasceno ROS, Amorati R, Elshabrawy HA, de Castro RD, Bezerra DP, Nunes VRV, Gomes RC, Lima TC. de Sousa DP, et al. Biomolecules. 2023 Jul 18;13(7):1144. doi: 10.3390/biom13071144. Biomolecules. 2023. PMID: 37509180 Free PMC article. Review.
-
Effects of Litsea cubeba Essential Oil Incorporated into Denture Soft Lining Materials.
Songsang N, Anunmana C, Pudla M, Eiampongpaiboon T. Songsang N, et al. Polymers (Basel). 2022 Aug 10;14(16):3261. doi: 10.3390/polym14163261. Polymers (Basel). 2022. PMID: 36015520 Free PMC article.
-
Chaiyasut C, Sivamaruthi BS, Wongwan J, Thiwan K, Rungseevijitprapa W, Klunklin A, Kunaviktikul W. Chaiyasut C, et al. Evid Based Complement Alternat Med. 2020 Jul 26;2020:4389239. doi: 10.1155/2020/4389239. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32774414 Free PMC article.
-
Li LH, Wu P, Lee JY, Li PR, Hsieh WY, Ho CC, Ho CL, Chen WJ, Wang CC, Yen MY, Yang SM, Chen HW. Li LH, et al. PLoS One. 2014 Aug 8;9(8):e104203. doi: 10.1371/journal.pone.0104203. eCollection 2014. PLoS One. 2014. PMID: 25105411 Free PMC article.
-
Mohamed Abdoul-Latif F, Ainane A, Houmed Aboubaker I, Mohamed J, Ainane T. Mohamed Abdoul-Latif F, et al. Pharmaceuticals (Basel). 2023 Jul 31;16(8):1086. doi: 10.3390/ph16081086. Pharmaceuticals (Basel). 2023. PMID: 37631000 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E (2011) Global cancer statistics. CA Cancer J Clin 66: 69–90. - PubMed
-
- Tyagi P, Belani CP, Jain VK (2005) Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small cell lung cancer: results from the SPIRIT I and II trials. Clin Lung Cancer 7: 17–19. - PubMed
-
- Schuurbiers Olga CJ, Kaanders JHAM, van der Heijden HFM, Dekhuijzen RPN, Oyen WJG, et al. (2009) The PI3-K/AKT-Pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761–767. - PubMed
-
- Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/Protein Kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986–3997. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
This research work was financially supported by the grant from CSIR-NEEP Project (HCP-005). The authors SS and PC are thankful to the Department of Science & Technology, Govt. of India, New Delhi; Sushmita Bhattacharya, DP and RK are indebted to Council of Scientific and Industrial Research (CSIR), New Delhi, for the award of Research Fellowships. SD is thankful to UGC for Dr. D. S. Kothari PDF & CSIR-NEIST for QHF; and Samir Bhattacharya to the Indian National Science Academy for his INSA Senior Scientist position. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous